JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28

Benzinga Newsdesk www.benzinga.com Neutral 59.6%

Neg 0% Neu 59.6% Pos 0%

JP Morgan analyst Brian Cheng initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Overweight rating and announces Price Target of $28.